Nuvalent Announces Public Offering of Common Stock

CAMBRIDGE, Mass., Oct. 31, 2022 /PRNewswire/ — Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced that it has commenced an underwritten public offering…

Click here to view original post